Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Summary not available.
Enanta Pharmaceuticals (NASDAQ: ENTA) will present clinical and preclinical data at the American Thoracic Society International Conference 2026 in Orlando, May 15–20, 2026. An oral presentation on zelicapavir (Phase 2) is scheduled for May 19, 2:15–2:27 PM EDT. Two posters on EPS-3903, an oral STAT6 inhibitor, will be shown May 19, 11:30 AM–1:15 PM EDT. Presenters include Christopher Harris, M.D., Yaohui Nie, Ph.D., Lisha Xu, and Yang Li, Ph.D. Presentation materials will be posted on the company website after each session.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the first participant has been dosed in a Phase 1 trial of EDP-978, an oral once-daily KIT inhibitor in development for chronic urticaria and other mast cell-driven diseases.
The randomized, double-blind, placebo-controlled SAD and MAD study will enroll approximately 98 healthy adults (18–65). The MAD includes a 14-day treatment period and the SAD includes a two-part food-effect cohort. Topline Phase 1 data, including serum tryptase biomarker effects, are expected in Q4 2026.
Enanta Pharmaceuticals (NASDAQ:ENTA) will present new clinical data for zelicapavir, an oral once-daily N‑protein inhibitor for RSV, at ESCMID Global 2026 on April 18, 2026 in Munich.
Presentations include Phase 2b high-risk adult results showing ~one week faster symptom resolution and lower hospitalization, plus pediatric data confirming a high barrier to antiviral resistance and strong exposure multiples over EC90.
Enanta Pharmaceuticals (NASDAQ: ENTA) will present four preclinical posters on its STAT6 inhibitor program at IMMUNOLOGY2026, April 15-19, 2026, in Boston. Presentations cover EPS-3903 tolerability, selectivity, pharmacokinetics, and activity in asthma and allergic disease models.
Each poster lists date, time, session, and presenters; posters will be posted on the company website after each presentation.
Enanta Pharmaceuticals (NASDAQ:ENTA) said members of management will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL.
According to Enanta, a live webcast will be available via the company’s Investors "Events and Presentations" page and a replay will be archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) will present preclinical data for EDP-978, its KIT inhibitor candidate for mast cell-mediated, Type 2 immune diseases, in two poster sessions at the 2026 AAAAI Annual Meeting in Philadelphia on February 27, 2026.
Posters (Numbers 104 and 038) in the Allergic Skin Diseases session are scheduled 2:45–3:45 PM EST and will be available on Enanta's website after the presentations; abstracts appear in the JACI online supplement.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported fiscal Q1 results for the quarter ended December 31, 2025 and highlighted progress across virology and immunology programs.
Key items: $241.9M in cash and marketable securities, ongoing Phase 3 enabling activities for zelicapavir, IND plans for EDP-978 and EPS-3903, and a new MRGPRX2 program with candidate selection targeted in 2H 2026.
Summary not available.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 3:00 p.m. PT in San Francisco.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.enanta.com, and a replay will be archived for at least 30 days following the presentation.